Microbiome Therapeutics Market Size

Microbiome Therapeutics Market size was valued at USD 531.37 million in 2024 and is set to reach USD 8.59 billion by the end of 2037, expanding at around 23.6% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of microbiome therapeutics is assessed at USD 632.54 million. The growth of the market can be attributed to the increasing proportion of several diseases comprising inflammatory bowel disease (IBD), obesity, allergic disorders, and so on caused by dysbiosis of microbiota in the gut throughout the world. For instance, currently, there are nearly 11 million individuals have been suffering from inflammatory bowel disease (IBD) across the globe. Further, the growing concerns amongst individuals about the beneficial microorganisms in the human body, growing age, and unhealthy lifestyle patterns are further factors that are projected to drive the global microbiome therapeutics market over the forecast period.

In addition to these, factors that are believed to proliferate the growth of the global microbiome therapeutics market include the radically rising investments in microbiome modulators, and escalating collaboration between major key players for producing novel microbiome therapeutics are also anticipated to fuel market growth in the coming years. For instance, on February 1, 2023, The University of Texas MD Anderson Cancer Center announced a strategic partnership with the global biopharma institute Federation Bio to rationally produce a novel microbiome treatment for immunotherapy-resistant cancer patients. Additionally, the surging awareness regarding microbiome therapeutics is also predicted to present the potential for market expansion over the projected period.